Posted by Michael Wonder on 12 Feb 2022
Health economic assessment of Jemperli in endometrial cancer
11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is intended for patients with endometrial cancer.
Jemperli has been investigated in a study that is still on-going. It is uncertain what effect the drug has on time to relapse and survival, respectively.
